Applicability of current prognostication models for MDS patients with DDX41 mutation
Nadia Toumeh(Mayo Clinic in Arizona), Aref Al‐Kali(Mayo Clinic), Abhishek A. Mangaonkar(Mayo Clinic), Mithun Vinod Shah(Mayo Clinic in Arizona), Dragan Jevremović(Mayo Clinic in Arizona), Rong He(Mayo Clinic), James M. Foran(Memorial Sloan Kettering Cancer Center), Aasiya Matin(Mayo Clinic in Arizona), Hassan B. Alkhateeb(Mayo Clinic), Yael Kusne(WinnMed), Mrinal M. Patnaik(Mayo Clinic), Patricia T. Greipp(Mayo Clinic), Talha Badar(Mayo Clinic in Florida), William J. Hogan(Mayo Clinic), Yazan Jabban(Mayo Clinic), David S. Viswanatha(Mayo Clinic), Antoine N. Saliba(Mayo Clinic in Arizona), Mehrdad Hefazi Thorghabeh(Mayo Clinic), Cecilia Y. Arana Yi(Mayo Clinic in Arizona)
Cited by 2
Related Papers
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2017|655
The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group
|Nature Reviews Nephrology|2018|544
Inherited antithrombin deficiency: a review
|Haemophilia|2008|396
Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2016|297